Affiliations: [a] Department of Public Health and Caring Sciences/Geriatrics, Faculty of Medicine, Uppsala University, Uppsala, Sweden | [b] Uppsala University, Department of Medical Sciences, Uppsala University, Uppsala, Sweden | [c] Department of Public Health and Caring Sciences/Oxidative stress and Inflammation, Faculty of Medicine, Uppsala University, Uppsala, Sweden | [d] Center of Excellence-Inflammation, Uppsala University Hospital, Uppsala, Sweden
Correspondence:
[*]
Corresponding author: Dr. S. Basu, Department of Public Health and Caring Sciences/Oxidative stress and Inflammation, Uppsala Science Park, Dag Hammarskölds väg 14B, SE-751 85 Uppsala, Sweden. Tel.: +46 18 611 79 58; Fax: +46 18 611 79 76; E-mail: [email protected].
Abstract: Oxidative stress in the brain is suggested to be involved in the pathophysiology of Alzheimer's disease (AD). In this study, serum α- and γ-tocopherol, the two major systemic antioxidants, were analyzed at two examinations of the ULSAM-study, a longitudinal, community-based study of elderly men (age 70, n = 616 and age 77, n = 761). In addition, urinary F2-isoprostane levels, as markers of systemic oxidative stress, were analyzed at the age of 77 in this cohort (n = 679). Cox regression analyses were used to examine associations between serum α-, γ-tocopherol and urinary F2-isoprostane levels and AD, any type of dementia (all-cause dementia) and non-AD dementia. On follow-up (median, 12.3 years), 40 subjects developed AD and 86 subjects developed all-cause dementia. Serum α- and γ-tocopherol or urinary F2-isoprostane levels were not associated with the future risk of AD or dementia. In conclusion, systemic serum α- and γ-tocopherol and urinary F2-isoprostane levels are not associated with the future risk of AD or dementia and do not seem to be useful predictors of clinical AD or dementia.
